{
  "label": "clinical_signal_03_ep_029",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:b05dfd05b2c5d6d044d5ad619187d12b854f7045486fb7ba70dc63335b9725de",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:53.069935",
  "content": "## 2024-09-16 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 222\n- Active: 202\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 20\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 52\n- Statin Subgroup ALT (U/L) Mean: 171.6\n- Statin Subgroup ALT (U/L) Median: 169.8\n- Statin Subgroup AST (U/L) Mean: 118.2\n- Statin Subgroup AST (U/L) Median: 118.1\n- Statin Subgroup Bilirubin (mg/dL) Mean: 2.77\n- Statin Subgroup Bilirubin (mg/dL) Median: 2.74\n- Statin Subgroup ALP (U/L) Mean: 82.0\n- Statin Subgroup ALP (U/L) Median: 68.1\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.87\n- Statin Subgroup Creatinine (mg/dL) Median: 0.82\n- Statin Subgroup BUN (mg/dL) Mean: 13.3\n- Statin Subgroup BUN (mg/dL) Median: 11.4\n- Statin Subgroup WBC (K) Mean: 8.2\n- Statin Subgroup WBC (K) Median: 5.7\n- Statin Subgroup Platelets (K) Mean: 234\n- Statin Subgroup Platelets (K) Median: 228\n- Non-Statin Subgroup N: 126\n- Non-Statin Subgroup ALT (U/L) Mean: 21.3\n- Non-Statin Subgroup ALT (U/L) Median: 21.0\n- Non-Statin Subgroup AST (U/L) Mean: 19.4\n- Non-Statin Subgroup AST (U/L) Median: 18.3\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.52\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 69.3\n- Non-Statin Subgroup ALP (U/L) Median: 68.1\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.85\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.91\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Non-Statin Subgroup BUN (mg/dL) Median: 12.7\n- Non-Statin Subgroup WBC (K) Mean: 6.4\n- Non-Statin Subgroup WBC (K) Median: 7.6\n- Non-Statin Subgroup Platelets (K) Mean: 232\n- Non-Statin Subgroup Platelets (K) Median: 258\n\n### Adverse Events\n- AE ID: AE-0120, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0121, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0122, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0123, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0124, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0125, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0126, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 23\n- ACE Inhibitor Count: 30\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-061, Description: Missed visit window (2 days late), Severity: minor, Site: site_09\n\n### Investigator Notes\n- Source document verification complete for prior monitoring visit\n- Training log updated for new study coordinator\n- All sites now operating under amended protocol v4.0\n\n### Events\n- Site 12 monitoring visit completed, 1 findings\n- Drug accountability audit at Site 05: no discrepancies\n\n### Notes\n- Week 29: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_029",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-09-16T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}